Efficacy of arsenic trioxide for acute promyelocytic leukemia: A systematic review and meta-analysis

Journal of Chinese Integrative Medicine

Volumn 7, Issue 9, 2009, Pages 801-808

  Xu, Shuang Nian ^a   Chen, Jie Ping ^a   Liu, Jian Ping ^b   Xia, Yun ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Arsenic trioxide; Leukemia, promyelocytic, acute; Meta analysis; Randomized controlled trial; Systematic review

Indexed keywords

ARSENIC TRIOXIDE; RETINOIC ACID; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; EDEMA; HUMAN; INCIDENCE; MEDICAL LITERATURE; META ANALYSIS; MORTALITY; OVERALL SURVIVAL; PROMYELOCYTIC LEUKEMIA; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; LEUKEMIA, PROMYELOCYTIC, ACUTE;

ANTINEOPLASTIC AGENTS; ARSENICALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES;

EID: 73849130574     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20090901     Document Type: Review

References (20)

1. Lu DP. Therapeutics of leukemia. Beijing: Science Press. 1992: 152. Chinese.
2. Ribeiro RC, Rego E. Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematology Am Soc Hematol Educ Program. 2006: 162-168.
3. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008; 111(5): 2505-2515.
4. Kelaidi C, Ades L, Chevret S, Sanz M, Guerci A, Thomas X, de Botton S, Raffoux E, Rayon C, Fegueux N, Bordessoule D, Rigal-Huguet F, Link H, Stoppa A, Vekhoff A, Meyer-Monard S, Castaigne S, Dombret H, Degos L, Fenaux P. Late first relapses in APL treated with all-trans- retinoic acid- and anthracycline-based chemotherapy: The European APL group experience (APL 91 and APL 93 trials). Leukemia. 2006; 20(5): 905-907.
5. Zhang TD, Li YS. Clinical analysis and experimental study of Ailing I in treatment of acute promyelocytic leukemia. Zhong Xi Yi Jie He Za Zhi. 1984; 4(1): 19-20. Chinese.
6. Ma J. Review of progress on treatment of acute promyelocytic leukemia with arsenic trioxide. Guo Ji Shu Xue Yu Xue Ye Xue Za Zhi. 2007; 30(3): 210-213. Chinese.
7. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. Oxford: The Cochrane Library. 2008.
8. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16.
9. Zhou J, Meng R, Wang Y, Yang BF. Clinical observation and following up of two administration methods of arsenic trioxide in treatment of acute promyelocytic leukemia. Zhonghua Yi Xue Za Zhi. 2004; 84(5): 405-408. Chinese with abstract in English.
10. Zhou J, Meng R, Yang BF. Comparing two arsenic trioxide administration methods in APL therapy. Chin Med J (Engl). 2004; 117(9): 1411-1413.
11. Zhou J, Meng R, Sui XH, Meng L, Jia J, Yang BF. Effects of administration styles of arsenic trioxide on intracellular arsenic concentration, cell differentiation and apoptosis. Haematologica. 2005; 90(9): 1277-1279.
12. Zhou J, Meng R, Sui XH, Meng L, Yang BF. Effects of arsenic trioxide administration styles on leukocytosis. Chin Med Sci J. 2006; 21(2): 111-114.
13. Zhou J, Meng R, Yang BF. Clinical effects of arsenic trioxide by slowing-intravenous infusion on acute promyelocyte leukemia. Chin Med Sci J. 2005; 20(2): 137.
14. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004; 101(15): 5328-5335.
15. Su XL, Xia WL. Clinical observation of all-trans retinoic acid and arsenic trioxide in treatment of newly diagnosed acute promyelocytic leukemia. Ji Ceng Yi Xue Lun Tan. 2006; 10(4): 338-339. Chinese.
16. Ren JH, Lin FR, Guo XN, Wang Y, Zhang JN, Wang Y, Dong ZR. Clinical observation of all-trans retinoic acid, arsenic trioxide and chemotherapy in treating acute promyelocytic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2004; 25(7): 437-438. Chinese.
17. Yang EQ, Liu ZM, He C. Efficacy of all-trans retinoic acid and arsenic trioxide in treatment of newly diagnosed acute promyelocytic leukemia. Bai Xue Bing Lin Ba Liu. 2006; 15(3): 216-217. Chinese.
18. Chen Z, Zhao WL, Shen ZX, Li JM, Chen SJ, Zhu J, Lallemand BV, Zhou J, Guillemin MC, Vitoux D, de The H. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological. Curr Top Microbiol Immunol. 2007; 313: 129-144.
19. 3 exerts dose-dependent dual effects on APL cells. Blood. 1997; 89(9): 3345-3353.
20. Douer D, Tallman M. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol. 2005; 23(10): 2396-2410.